Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACADIA Pharmaceuticals

15.38
-0.7400-4.59%
Post-market: 15.400.0200+0.13%17:43 EDT
Volume:2.16M
Turnover:33.35M
Market Cap:2.57B
PE:11.31
High:15.97
Open:15.93
Low:15.28
Close:16.12
Loading ...

Company Profile

Company Name:
ACADIA Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1993
Employees:
654
Office Location:
12830 El Camino Real,Suite 400,San Diego,California,United States
Zip Code:
92130
Fax:
858 212 0513
Introduction:
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

Directors

Name
Position
Stephen R. Davis
Director and Chief Executive Officer
Stephen R. Biggar
Chair of the Board and Director
Adora Ndu
Director
Daniel Soland
Director
Edmund Harrigan
Director
Elizabeth A. Garofalo
Director
James Daly
Director
Julian Baker
Director
Laura Brege
Director

Shareholders

Name
Position
Stephen R. Davis
Director and Chief Executive Officer
Brendan P. Teehan
Executive Vice President, Chief Operating Officer and Head of Commercial
Mark C. Schneyer
Executive Vice President, Chief Financial Officer
Austin D. Kim
Executive Vice President, General Counsel and Secretary
Douglas J. Williamson
Executive Vice President, Research and Development